Amyloid PET Imaging: Standard Procedures and Semiquantification.

Area of Science:

• Neurology
• Radiochemistry
• Medical Imaging

Background:

• Amyloid plaques are key indicators of Alzheimer's disease (AD) pathology.
• Positron Emission Tomography (PET) enables in vivo imaging of these plaques.
• Radiopharmaceuticals targeting amyloid-β plaques are crucial for Amyloid PET (Amy-PET).

Purpose of the Study:

• To review and compare available radiotracers for Amy-PET.
• To outline interpretation criteria for Amy-PET imaging.
• To summarize quantification methods for Amy-PET.

Main Methods:

• Review of validated Amy-PET radiotracers, including 11C-Pittsburgh compound B and 18F-labeled agents (e.g., 18F-florbetaben, 18F-florbetapir, 18F-flutemetamol).
• Discussion of visual/qualitative, semiquantitative, and quantitative interpretation methods.
• Summary of proposed quantification techniques for Amy-PET data.

Main Results:

• Several radiotracers for Amy-PET have been successfully validated.
• Diverse interpretation criteria (visual, semiquantitative, quantitative) are proposed for Amy-PET images.
• Various quantification methods are available for analyzing Amy-PET data.

Conclusions:

• Understanding the differences between Amy-PET radiotracers is essential for accurate Alzheimer's disease diagnosis.
• Standardized interpretation and quantification methods are key for reliable Amy-PET results.
• Amy-PET imaging offers valuable insights into AD neuropathology.